Corrigendum to "Immunogenic gangliosides in human ovarian carcinoma" [Biochem. Biophys. Res. Commun. 353 (2007) 251-258] (DOI:10.1016/j.bbrc.2006.12.001);Immunogenic gangliosides in human ovarian carcinoma

Biochemical and Biophysical Research Communications

Volumn 353, Issue 2, 2007, Pages 251-258

  Ravindranath, Mepur H ^a   Muthugounder, Sakunthala ^a   Presser, Naftali ^a   Selvan, Senthamil R ^b   Santin, Alessandro D ^c   Bellone, Stefania ^c   Saravanan, Thiruverkadu S ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Anti ganglioside IgM antibodies; Anti GD1a IgM; Ascitic fluid; Immunogenic gangliosides; Ovarian epithelial carcinoma; Plasma; Total gangliosides

Indexed keywords

GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GD2; GANGLIOSIDE GM2; GANGLIOSIDE GM3; IMMUNOGLOBULIN M;

ADULT; AGED; ARTICLE; ASCITES FLUID; CANCER CELL CULTURE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LIPID BLOOD LEVEL; MICROENVIRONMENT; OVARY CARCINOMA; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33845742673     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.09.103     Document Type: Erratum

References (35)

1. Ravindranath M.H., and Morton D.L. Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines. Cancer Invest. 15 (1997) 491-499
2. Birkl S., Zeng G., Gao L., Yu R.K., and Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie 85 (2003) 455-463
3. Yoshida S., Fukumoto S., Kawaguchi H., Sato S., Ueda R., and Furukawa K. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of proliferation and mediation of apoptosis. Cancer Res. 61 (2001) 4244-4252
4. Merzak A., Koochekpour S., McCrea S., Roxanis Y., and Pilkington C.J. Gangliosides modulate proliferation, migration, and invasiveness of human brain tumor cells in vitro. Mol. Chem. Neuropathol. 24 (1995) 121-135
5. Alessandri G., Cornaglia-Ferraris P., and Gullino P.M. Angiogenic and angiostatic microenvironment in tumors-role of gangliosides. Acta Oncol. 36 (1997) 383-387
6. Bergelson L.D. Plasma gangliosides as endogenous immuno-modulators. Immunol. Today 46 (1995) 483-486
7. Irie R.F., and Morton D.L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc. Natl. Acad. Sci. USA 83 (1986) 8694-8698
8. Livingston P.O. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev. 145 (1995) 147-166
9. Ravindranath M.H., and Morton D.L. Role of gangliosides in active immunotherapy with melanoma vaccine. Int. Rev. Immunol. 7 (1991) 303-329
10. Freimer M.L., McIntosh K., Adams R.A., Alving C.R., and Drachman D.B. Gangliosides elicit a T-cell independent antibody response. J. Autoimmun. 6 (1993) 281-289
11. Davis A.C., Roux K.H., and Shulman M.J. On the structure of polymeric IgM. Eur. J. Immunol. 18 (1988) 1001-1008
12. Randall T.D., King L.B., and Corley R.B. The biological effects of IgM hexamer formation. Eur. J. Immunol. 20 (1990) 971-979
13. Randall T.D., Parkhouse R.M., and Corley R.B. J chain synthesis and secretion of hexameric IgM is differentially regulated by lipopolysaccharide and interleukin 5. Proc. Natl. Acad. Sci. USA 89 (1992) 62-66
14. Ravindranath M.H., Muthugounder S., Presser N., Ye W., Brosman S., and Morton D.L. Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer. Biochem. Biophys. Res. Commun. 324 (2004) 154-165
15. Mazzoni A., Trave F., Fabbri M., Leto G., and Ghidoni R. Membrane gangliosides and immuno-mediated cytolysis in drug sensitive and treatment-induced multidrug resistant human ovarian cancer cells. Anticancer Res. 11 (1991) 2181-2185
16. Prinetti A., Basso L., Appierto V., Villani M.G., Valsecchi M., Loberto N., Prioni S., Chigorno V., Cavadini E., Formelli F., and Sonnino S. Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J. Biol. Chem. 278 (2003) 5574-5583
17. Novikov A.M., Makhova E.E., Travnikov M.E., and Bassalyk L.S. Ganglioside content and profile in the ovarian tumor tissues and in the biological body fluids of patients. Eksp Onkol. 11 (1989) 52-55
18. Andreasian G.O., Malykh I.N., and Dyatlovitskaia E.V. Ceramides and gangliosides in benign and malignant human ovarian tumors. Vopr. Med. Khim. 42 (1996) 248-253
19. Dyatlovitskaya E.V., Andreasyan G.O., Malykh Y., Rylova S.N., and Somova O.G. Ganglioside shedding and changes in ceramide biosynthesis in human ovarian tumors. Biochemistry (Mosc). 6 (1997) 557-561
20. Dolo V., Li R., Dillinger M., Flati S., Manela J., Taylor B.J., Pavan A., and Ladisch S. Enrichment and localization of ganglioside G(D3) and caveolin-1 in shed tumor cell membrane vesicles. Biochim. Biophys. Acta 1486 (2000) 265-274
21. Ravindranath M.H., Muthugounder S., Presser N., Ye X., Brosman S., and Morton D.L. Endogenous immune response to gangliosides in patients with confined prostate cancer. Int. J. Cancer 116 (2005) 368-377
22. Selvan R.S., Malone C.C., Cornforth A.N., Beutel L., and Dillman R.O. Established ovarian cancer cells as allogeneic tumor cell vaccine for adjuvant treatment of advanced ovarian cancer. J. Immunother. 22 (2000) 601
23. Ravindranath M.H., Muthugounder S., Saravanan T.S., Presser N., and Morton D.L. Human antiganglioside autoantibodies. Validation of ELISA. Ann. NY Acad. Sci. 1050 (2005) 229-242
24. Chu K.U., Ravindranath M.H., Gonzales A., Nishimoto K., Tam W.T., Soh D., Bilchik A., Katopodis N., and Morton D.L. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer 88 (2000) 1828-1836
25. Ravindranath M.H., Wood T.F., Soh D., Gonzales A., Muthugounder S., Perez C., Morton D.L., and Bilchik A. Cryosurgical ablation of liver tumors in colon cancer patients increases the plasma total ganglioside level and then selectively augments antiganglioside IgM. Cryobiology 45 (2002) 10-21
26. Perez C.A., Ravindranath M.H., Soh D., Gonzales A., Ye W., and Morton D.L. Plasma antiganglioside IgM antibodies in soft tissue sarcoma: Clinical prognostic implications. Cancer J. 8 (2002) 384-394
27. Ravindranath M.H., Bauer P.M., Cornillez-Ty C., Garcia J., and Morton D.L. Quantitation of the density of cell-surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA. J. Immunol. Methods 197 (1996) 51-67
28. Ravindranath M.H., Ravindranath R.M.H., Morton D.L., and Graves M.C. Factors affecting the fine specificity and sensitivity of plasma antiganglioside antibodies in ELISA. J. Immunol. Methods 169 (1994) 257-272
29. Reynolds C.P., Maurer B.J., and Kolesnick R.N. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett. 206 (2004) 69-80
30. Cabot M.C. Ceramide glycosylation and chemotherapy resistance. In: Futerman A.H. (Ed). Ceramide Signaling (2002), Kluwer Academic, NY 133-139 (Chapter 14)
31. Kanda N., and Watanabe S. Ganglioside GD1a enhances immunoglobulin production by human peripheral blood mononuclear cells. Exp. Hematol. 28 (2000) 672-679
32. Fitzgerald K.A., O'Neill L.A.J., Gearing A.J.H., and Callard R.E. The Cytokine, Facts Book (2004), Academic Press, San Diego
33. Watson J.M., Sensintaffar J.R., Berek J.S., and Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. (1990) 6959-6965
34. Scambia G., Testa U., Panici P.B., Martucci R., Foti E., Petrini M., Amoroso M., Masciullo V., Peschle C., and Mancuso S. Interleukin-6 plasma levels in patients with gynecological tumors. Int. J. Cancer 57 (1994) 318-323
35. Santin A.D., Bellone S., Ravaggi A., Roman J., Smith C.V., Pecorelli S., Cannon M.J., and Parham G.P. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 108 (2001) 804-808